Summary: MAPS Founder and Executive Director Rick Doblin, Ph.D., will be presenting as a keynote speaker at the inaugural PsyTech Summit in Tel Aviv, Israel, from March 29-30, 2020. Saul Kaye, Founder and CEO of iCAN, the parent organization of PsyTech, says that he is excited for Doblin “to share his enlightened vision and vast knowledge of the fast-developing therapeutic ecosystem that is about to explode as a wave of new information, research and consumer interest about psychedelics floods the market.”
Originally appearing here.
TEL AVIV, Israel, Jan. 13, 2020 — PsychedeliTech, a new and ground-breaking conference, incubator and discovery platform for psychedelic medicine is proud to announce that Rick Doblin, Ph.D., Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS) will be the keynote speaker at the first-ever PsyTech Summit, a forum for psychedelic science, innovation and investment conference in Israel.
The inaugural PsyTech conference will take place March 29-30, 2020 at the Hilton Hotel, on the Mediterranean Sea in Tel Aviv, Israel.
PsyTech is a division of iCAN: Israel-Cannabis, which together with CannaTech, its medical cannabis events platform, has been a force in education and innovation for the best cannabis therapeutics and products around the world.
Saul Kaye, iCAN founder and CEO, said, “Rick Doblin is an early pioneer and extremely effective advocate for the potential of psychedelics in the treatment of mental health disease and symptoms, including depression, anxiety disorders, and PTSD. We are thrilled he will join us at our first PsyTech Summit in Tel Aviv to share his enlightened vision and vast knowledge of the fast-developing therapeutic ecosystem that is about to explode as a wave of new information, research and consumer interest about psychedelics floods the market.”
Psychedelics have the chance to impact mental health with the global market for mental health medications worth $88.3 billion in 2015, according to BCC Research.
“For the first 30 years of MAPS’ work, there were virtually no for-profit psychedelic business opportunities, apart from a few ibogaine and ayahuasca clinics and mushroom sales in countries where the substances were not illegal. The new for-profit entities now emerging in the field of psychedelics, due to the success of non-profit psychedelic therapy research and advocacy, will need to focus on public benefit as well as profit in order to avoid a cultural backlash against these historically misunderstood substances. I am looking forward to discussing these important issues at PsyTech, Israel’s first summit focusing on the therapeutic potential of psychedelics,” said Doblin.
Similar to the cannabis industry, psychedelics and medicinal mushrooms will require an ecosystem to effectively drive education, regulation, safety, investment, research and development. These key issues, as well as personal stories of treatment, will be explored at PsyTech.
